Publikationen - Prof. Dr. Joseph Rosenecker

  • Publikationen – 2013

    Cystic fibrosis transmembrane conductance regulator-mRNA delivery: a novel alternative for cystic fibrosis gene therapy.
    Bangel-Ruland N, Tomczak K, Fernández Fernández E, Leier G, Leciejewski B, Rudolph C, Rosenecker J, Weber WM.
    J Gene Med. 2013 Nov-Dec;15(11-12):414-26. doi: 10.1002/jgm.2748.

  • Publikationen – 2012

    Lentiviral small hairpin RNA delivery reduces apical sodium channel activity in differentiated human airway epithelial cells.
    Aarbiou J, Copreni E, Buijs-Offerman RM, van der Wegen P, Castellani S, Carbone A, Tilesi F, Fradiani P, Hiemstra PS, Yueksekdag G, Diana A, Rosenecker J, Ascenzioni F, Conese M, Scholte BJ.
    J Gene Med. 2012 Dec;14(12):733-45. doi: 10.1002/jgm.2672.


    Formation of solid lipid nanoparticle (SLN)-gene vector complexes for transfection of mammalian cells in vitro.
    Rudolph C, Rosenecker J.
    Cold Spring Harb Protoc. 2012 Mar 1;2012(3):357-60. doi: 10.1101/pdb.prot068122.


    Characterization of Ku70(2)-NLS as bipartite nuclear localization sequence for non-viral gene delivery.
    Matschke J, Bohla A, Maucksch C, Mittal R, Rudolph C, Rosenecker J.
    PLoS One. 2012;7(2):e24615. doi: 10.1371/journal.pone.0024615. Epub 2012 Feb 8.


    Albert Uffenheimer: pediatrician and public health advocate before Nazi rule.
    Autenrieth A, Thal W, Rosenecker J.
    Isr Med Assoc J. 2011 May;13(5):270-2.

  • Publikationen – 2011

    Gene and cell therapy for cystic fibrosis: from bench to bedside.
    Conese M, Ascenzioni F, Boyd AC, Coutelle C, De Fino I, De Smedt S, Rejman J, Rosenecker J, Schindelhauer D, Scholte BJ.
    J Cyst Fibros. 2011 Jun;10 Suppl 2:S114-28. doi: 10.1016/S1569-1993(11)60017-9. Review.


    PEGylation improves nanoparticle formation and transfection efficiency of messenger RNA.
    Uzgün S, Nica G, Pfeifer C, Bosinco M, Michaelis K, Lutz JF, Schneider M, Rosenecker J, Rudolph C.
    Pharm Res. 2011 Sep;28(9):2223-32. doi: 10.1007/s11095-011-0464-z. Epub 2011 May 19.


    Expression of therapeutic proteins after delivery of chemically modified mRNA in mice.
    Kormann MS, Hasenpusch G, Aneja MK, Nica G, Flemmer AW, Herber-Jonat S, Huppmann M, Mays LE, Illenyi M, Schams A, Griese M, Bittmann I, Handgretinger R, Hartl D, Rosenecker J, Rudolph C.
    Nat Biotechnol. 2011 Feb;29(2):154-7. doi: 10.1038/nbt.1733. Epub 2011 Jan 9.

  • Publikationen – 2010

    The long and winding road to clinical success in gene therapy.
    Rosenecker J.
    Curr Opin Mol Ther. 2010 Oct;12(5):507-8. Review. No abstract available.


    Dynamics of magnetic particles in cylindrical Halbach array: implications for magnetic cell separation and drug targeting.
    Babinec P, Krafcík A, Babincová M, Rosenecker J.
    Med Biol Eng Comput. 2010 Aug;48(8):745-53. doi: 10.1007/s11517-010-0636-8. Epub 2010 Jun 2.


    Repeated siRNA application is a precondition for successful mRNA gammaENaC knockdown in the murine airways.
    Yueksekdag G, Drechsel M, Rössner M, Schmidt C, Kormann M, Illenyi MC, Rudolph C, Rosenecker J.
    Eur J Pharm Biopharm. 2010 Aug;75(3):305-10. doi: 10.1016/j.ejpb.2010.04.005. Epub 2010 Apr 18.

  • Publikationen – 2009

    Magnetofection: the use of magnetic nanoparticles for nucleic acid delivery.
    Plank C, Rosenecker J.
    Cold Spring Harb Protoc. 2009 Jun;2009(6):pdb.prot5230. doi: 10.1101/pdb.prot5230. No abstract available.


    Respiration triggered magnetic drug targeting in the lungs.
    Dahmani Ch, Götz S, Weyh T, Renner R, Rosenecker M, Rudolph C.
    Conf Proc IEEE Eng Med Biol Soc. 2009;2009:5440-3. doi: 10.1109/IEMBS.2009.5332476.


    Airway surface liquid contains endogenous DNase activity which can be activated by exogenous magnesium.
    Rosenecker J, Naundorf S, Rudolph C.
    Eur J Med Res. 2009 Jul 22;14(7):304-8.


    Recent advances in magnetofection and its potential to deliver siRNAs in vitro.
    Mykhaylyk O, Zelphati O, Hammerschmid E, Anton M, Rosenecker J, Plank C.
    Methods Mol Biol. 2009;487:111-46. doi: 10.1007/978-1-60327-547-7_6.


    Current prospects for mRNA gene delivery.
    Yamamoto A, Kormann M, Rosenecker J, Rudolph C.
    Eur J Pharm Biopharm. 2009 Mar;71(3):484-9. doi: 10.1016/j.ejpb.2008.09.016. Epub 2008 Oct 10. Review.


    Epithelial sodium channel inhibition in primary human bronchial epithelia by transfected siRNA.
    Caci E, Melani R, Pedemonte N, Yueksekdag G, Ravazzolo R, Rosenecker J, Galietta LJ, Zegarra-Moran O.
    Am J Respir Cell Mol Biol. 2009 Feb;40(2):211-6. doi: 10.1165/rcmb.2007-0456OC. Epub 2008 Aug 21.

  • Publikationen – 2008

    siRNA delivery by magnetofection.
    Mykhaylyk O, Zelphati O, Rosenecker J, Plank C.
    Curr Opin Mol Ther. 2008 Oct;10(5):493-505. Review.


    Cell type differences in activity of the Streptomyces bacteriophage phiC31 integrase.
    Maucksch C, Aneja MK, Hennen E, Bohla A, Hoffmann F, Elfinger M, Rosenecker J, Rudolph C.
    Nucleic Acids Res. 2008 Oct;36(17):5462-71. doi: 10.1093/nar/gkn532. Epub 2008 Aug 21.


    Targeted delivery of magnetic aerosol droplets to the lung.
    Dames P, Gleich B, Flemmer A, Hajek K, Seidl N, Wiekhorst F, Eberbeck D, Bittmann I, Bergemann C, Weyh T, Trahms L, Rosenecker J, Rudolph C.
    Nat Nanotechnol. 2007 Aug;2(8):495-9. doi: 10.1038/nnano.2007.217. Epub 2007 Jul 22.